Misclassification of Variants As Pathogenic in Black Americans

Share this content:
Misclassification of Variants As Pathogenic in Black Americans
Misclassification of Variants As Pathogenic in Black Americans

THURSDAY, Aug. 18, 2016 (HealthDay News) -- Variants that have previously been considered causal in hypertrophic cardiomyopathy are often misclassified as pathogenic in patients with African or unspecified ancestry, according to a study published in the Aug. 18 issue of the New England Journal of Medicine.

Arjun K. Manrai, Ph.D., from Harvard Medical School in Boston, and colleagues identified variants that have previously been considered causal in hypertrophic cardiomyopathy and are overrepresented in the general population. These variants were studied in diverse populations and reevaluated in the medical literature. Patient records at a leading genetic-testing laboratory were reviewed for occurrences of these variants.

The researchers found that multiple patients of African or unspecified ancestry received positive reports, with variants misclassified as pathogenic. On subsequent re-categorization, all variants were benign. The most common mutations in the general population were significantly more common among black than white Americans (P < 0.001). These misclassifications probably would have been prevented by inclusion of even small numbers of black Americans in control cohorts.

"These results expand on current guidelines, which recommend the use of ancestry-matched controls to interpret variants," the authors write. "As additional populations of different ancestry backgrounds are sequenced, we expect variant reclassifications to increase, particularly for ancestry groups that have historically been less well studied."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »